Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by nemo3on Jan 31, 2020 12:13pm
123 Views
Post# 30625993

FDA Ph 2 and ph 3 divergent results on 22 trials

FDA Ph 2 and ph 3 divergent results on 22 trialsI am one that hopes that TLT will show a very high efficacy rate in Ph 2.  If Ph 2 results are great then we may not need a Ph 3.  But for those that have had to go to Ph 3, favorable Ph 2 results do not mean Ph 3 will be favorable. 

So while I hope that TLT will be the next treatment of choice that works for NMBIC we still need to see what numbers we get for success in Ph 2.  If TLT results in Ph 2 are good but still necessitate a Ph 3, then clearly we could be a treatment that shows itself not to be as good as we are all hoping it will be.

Here is a link to the FDA that shows how 22 trials that did well in Ph 2 were not shown to be as favorable in Ph 3.  Just for info as we wait....

https://www.fda.gov/media/102332/download
Bullboard Posts